Tissue Regenix Share Discussion Threads

[bamboo2] 26/11/2014 11:21

70m trade !

at 21.457p

Guess we'll be getting an rns.

Wonder who the new holder is going to be?

[multibagger] 26/11/2014 06:25

O/T FAO Bamboo2....NIPT may be worth researching and looks fairly interesting...I took a massive hit thru' its predecessor VIY and still have legacy shares...no hard feelings, as it comes with the territory.

CTP is still very cheap....good luck :)

[rayrac] 25/11/2014 15:35

Sorry luminoso, I'll stay stum from here.😀

[luminoso] 25/11/2014 13:14

Go easy on the promotion of these elsewhere, Ray ! I am still waiting for something else to pay me off so I can get in here. :-)

[rayrac] 25/11/2014 08:51

Great news it is!

[bamboo2] 25/11/2014 08:32

25 November 2014

Tissue Regenix Group Plc

Tissue Regenix receives notice of allowance for US meniscus patent

YORK, 25 November 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, has received notification from the United States Patent & Trademark Office (USPTO) that it will be granted a patent covering its dCELL(R) meniscus.

Tissue Regenix is currently developing a process for decellularising donated human meniscus, based on the porcine dCELL(R) Meniscus, which is starting a regulatory human clinical trial in the EU to secure a CE mark. Like the animal tissue product this would be a piece of decellularised human meniscus for use in partial meniscal replacement (which accounts for 80% of procedures) rather than as a full transplant.

The global sports medicine market was estimated at $6.1bn in 2012 with CAGR growth of 4.4% driving it to $8.2bn in 2019. Geographically, North America was said to account for the largest share of the global market in 2012 at just under $2.5bn .

'Minimally manipulated' human tissues are designated as transplants by the FDA and do not require approvals in the same way as medical devices. This could see a decellularised human meniscus launched in the US in the next two years.

Tissue Regenix's dCELL(R) meniscus will be used to repair damage from 'tears' in the meniscus knee cartilage as a result of acute injury such as sports injuries. Meniscal injuries affect around 1.5 million people per year in Europe and the US. The dCELL(R) meniscus has the potential to address this unmet clinical need as there are no implants available in the US at present.

This is the latest US patent covering the use of the dCELL(R) decellularisation process and follows the announcement in May 2014 that a patent, related to tissue matrices for bladder implantation, has been granted.

Antony Odell, CEO of Tissue Regenix commented: "This meniscus patent marks an important step forward in our US strategy as it defines our intellectual property for both human & animal tissue meniscus products in the world's largest market for sports medicine. It enables us to pursue, with confidence, the second phase of the roll-out of the Group's US human tissue strategy following the successful launch of DermaPure(TM) in June 2014."

Tissue Regenix has offices in the UK and US and is concentrated on the global commercialisation of its dCELL(R) technology.

Sports Medicine Devices Market - Global Industry Analysis, Size, Share, Growth Trends and Forecast, 2013-2019.

[bamboo2] 20/11/2014 14:00

Cheers Ray, bobs,

I think some clarification with regard to the proposed new HQ in York would be in order. Is the ex-Covidien building in addition to, or instead of the new build?
This wasn't made clear at the Capital Markets meeting. Anyone want to volunteer to email the co?

The kind of US info I would like to see over the next few months would consist of further validation from testimonials, some 'before and after' treatment photos and confirmation of the start of commercial operations.

Initial results from the Dermapure trial should be evident within a few months, early publication would indicate a very positive outcome.

[bobsgonnamakemerich] 18/11/2014 22:39

bb I would just be happy to see a few more testimonials from practitioners in the U.S. to keep our profile up.

I hope you are right about the trial but I am less confident about a near term update.

[rayrac] 18/11/2014 13:10

Just in case you were feeling lonely bamboo. I'm still here, fully committed.☺5039;

[bamboo2] 18/11/2014 08:47

A little more, desperately needed volume yesterday, and a good start today.
I'm hopeful we could be getting an interim progress report from the US before xmas.

[bamboo2] 14/11/2014 09:21

It looks to me likely that the co is effectively contracting out the production of all human based product, both here and in the US. Bovine derived production will presumably be in-house at the ex-Covidien building in leeds.

This makes sense because it creates a solid demarcation line between the two sources of our ECM's and should prevent the possibility of any confusion. I'm guessing that UK production of human based ECM will be left in the hands of NHSBT and Leeds Uni to maintain their closed loop.

[bamboo2] 13/11/2014 20:44

Some interesting references to TRX here, particularly to the basic research being done in colaboration with NHSBT/Leeds Uni that will lead to our next generation of products. [Bladder, Heart Valve, Tendon etc.]

[bamboo2] 09/11/2014 21:48

gb, mb, thanks for the posts.

Re, the figs from Jeffries, interesting.

dCell Meniscus is actually two different products.

In the US dCell meniscus is to be derived from human sources, so I would guess they would have similar problems to the current situation in the UK with a limited supply of good quality material for processing. This will obviously be a drag on potential sales figures.

In the UK and Europe dCell Meniscus is to be derived from bovine sources so supply is virtually unlimited, I think this product could eventually compete with the artificial joint replacement market and could be a game changer.

The US treats 1.5m DFU's per year.
From my research, Dermapure could potentially become the treatment of choice, with only one other competitor producing a similar ECM [but using a different process]. If TRX picked up just 10% of the market at $100/per treatment that would be a turnover of $15m.
Then add in VLU's, General Surgical and Dental...


...Still the chart looks primed and ready to go up.

[multibagger] 08/11/2014 13:42

Hi BB2,

The article is called Big Ideas from Biotech, page 34, Shares, 06 Nov 2014

Other shares also mentioned e-Therapeutics (ETX)
ReNeuron (RENE)

Nothing new...but according to Jeffries International its analysts are forecasting the product (Dermapure)will generate sales of $5.2m in the next 18 months and $21m in 2017.

Jeffries forecasts that DCell Meniscus product if approved in late 2016 will be launched in US and Europe in 2017 will generate $5.6m in sales and $19.4m a year later....

As I have been saying biotech is hot at the moment.....my ISAs in AXA Framlington biotech fund is approx 49% up since last year. Good sector to be in over the next 5-10 years along with technology funds.

Good luck all :)

O/T Take a look at CTP...DoI: I hold a fair few !

[grahamburn] 08/11/2014 10:01

There was also a very brief one sentence mention in a lengthy Investors Chronicle online article yesterday entitled "Is there still value in the biotech boom? Sector Focus".

"(TRX) has also rewarded shareholders this year: the shares rose 150 per cent in nine months to May ahead of the launch of its Dermapure product in the US."

[bamboo2] 08/11/2014 08:25

Hi mb, Thanks for letting us know.
The article's behind a paywall, is there anything in it that is new?

[multibagger] 08/11/2014 08:04

TRX mentioned in the latest Shares magazine, so may generate some interest.

[nashwan123] 05/11/2014 10:15

The product is life changing for many suffering with open wounds and a cause for multiple GP, hospital and Community Nurse visits. If this can gain traction it would significantly reduce NHS costs for this condition.
I need to check the figures to see what existing and potential revenue is in the next 3 years. This could be a multibagger albeit with 650M shares and unknown options in situ.

[rayrac] 05/11/2014 08:32

Yes, it's volume we need!
TRX is not on everyone's radar, by the proverbial mile.

[bamboo2] 05/11/2014 08:14

Brilliant news. Well done Antony Odell, Greg Bila and all.

Perhaps this will trigger some volume to get the share price moving.

[bamboo2] 04/11/2014 08:02

Re, chart, There's a possibility we could revisit 20p for anyone thinking of adding.
Edit, looking more closely, the small head and shoulders target is actually 21p. [approx 70% chance]